TRUDHESA Drug Patent Profile

Which patents cover Trudhesa, and what generic alternatives are available?

Trudhesa is a drug marketed by Impel Pharms and is included in one NDA. There are six patents protecting this drug.

This drug has sixty-four patent family members in sixteen countries.

The generic ingredient in TRUDHESA is dihydroergotamine mesylate. There are six drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the dihydroergotamine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Trudhesa

A generic version of TRUDHESA was approved as dihydroergotamine mesylate by PADAGIS US on April 28^th, 2003.

Summary for TRUDHESA

International Patents:	64
US Patents:	6
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TRUDHESA

TRUDHESA is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes			Y
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes			Y
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes			Y
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes			Y
Impel Pharms	TRUDHESA	dihydroergotamine mesylate	SPRAY, METERED;NASAL	213436-001	Sep 2, 2021		RX	Yes	Yes			Y

International Patents for TRUDHESA

See the table below for patents covering TRUDHESA around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2017113604	НАКОНЕЧНИКИ ДЛЯ НАЗАЛЬНОЙ ДОСТАВКИ ЛЕКАРСТВЕННЫХ СРЕДСТВ
China	107376071	用于将化合物递送到使用者的上部嗅觉区的喷嘴 (Nozzle for use in delivering a mixture of aerosol propellant and drug formulation)
China	103917265	Nasal drug delivery device
Brazil	112013022249	dispositivo de distribuição de droga nasal
Japan	6959708
European Patent Office	3679971	DISPOSITIF D'ADMINISTRATION DE MÉDICAMENT PAR VOIE NASALE (NASAL DRUG DELIVERY DEVICE)
Brazil	122021002471	DISPOSITIVO DE DISTRIBUIÇÃO DE DROGA NASAL

Investment Scenario and Fundamentals Analysis for Trudhesa

Last updated: February 20, 2026

What is Trudhesa?

Trudhesa (generic: dihydroergotamine mesylate) is a nasal spray approved by the FDA in January 2023 for the acute treatment of migraine with or without aura in adults. It is marketed by Flexion Therapeutics, now part of Pliant Therapeutics following a 2022 acquisition.

Market and Revenue Potential

Target Market: Estimated at 39 million adults with migraine in the U.S. (American Migraine Foundation, 2022). The immediate treatment segment constitutes roughly 30% of these patients, translating into a potential addressable market of approximately 11.7 million individuals.

Pricing and Pricing Strategy:

• Price per unit: $70–$90
• Presuming an average of two doses per migraine attack, with an estimated 4.7 migraine days/month per patient, annual market penetration could reach 2 million patients with an average of 12 doses/month.

Revenue Estimation:

Metric	Assumption	Calculation
Average doses/month per patient	12	2 doses per attack × 6 attacks/month
Price per dose	$80
Total patients	2 million
Monthly revenue	2 million patients × 12 doses × $80	$1.92 billion
Annual revenue	$1.92 billion × 12 months	$23 billion

Note: Actual revenue depends on market penetration, physician adoption, and formulary inclusion.

Market Share Outlook:

• Initial market penetration estimated at 5–10% in the first 2 years.
• Long-term market share could reach 30% as awareness and reimbursement improve.

Competitive Landscape

Main competitors include:

• Sumatriptan (Imitrex): Oral, nasal, injectable options; established, ~$600 million annual sales globally.
• Zembrace (Zolmitriptan nasal spray): Estimated at $150 million.
• Nurtec ODT (rimegepant): Oral tablet, $200+ million in 2022.
• Lasmiditan (Reyvow): $100+ million sales; CNS side effects limit use.

Trudhesa's nasal delivery offers rapid onset, appealing for acute treatment. Its differentiated mechanism and route position it as a potential preferred therapy.

Regulatory and Reimbursement Environment

• FDA approval early in 2023.
• Payer coverage likely prioritizes drugs with demonstrated clinical benefit and cost-effectiveness.
• Brand recognition and formulary inclusion are critical for uptake.

Investment Considerations

Strengths:

• First FDA-approved nasal dihydroergotamine, filling a treatment gap.
• Large global migraine market with growing awareness.
• Potential for high-market share if reimbursement and physician adoption accelerate.

Risks:

• Competitive pressure from established therapies.
• Limited data on long-term safety and efficacy post-approval.
• Pricing pressures and payer negotiations could limit margins.
• Dependence on physician acceptance and patient adherence.

Financial Outlook:

• Revenue is post-launch with initial ramp-up.
• Marketing investment and physician education expenses are expected.
• Operating margins could improve as sales scale if cost controls are maintained.

Valuation Implications:

• Early-stage revenue estimates are optimistic; conservative projections for 3-year horizon suggest $1–5 billion revenue.
• Valuation multiples for biotech/pharma stocks range from 3x to 8x sales, implying potential enterprise value from $3 billion to $40 billion.

Key Strengths and Weaknesses Summary

Strengths	Weaknesses
First nasal route approved for DHE	Limited long-term safety data
Large, unmet market	Competitive landscape with entrenched therapies
Differentiated delivery method	Potential pricing pressures

Key Takeaways

• Trudhesa has a sizeable near-term market opportunity based on migraine prevalence and nasal delivery preference.
• Revenue growth depends on early adoption, reimbursement, and competitive positioning.
• Risks relate to competition, payer dynamics, and long-term safety data.

FAQs

How does Trudhesa compare to traditional migraine treatments?

Trudhesa offers rapid relief via nasal spray, targeting patients seeking quick onset, especially those who cannot tolerate oral medications. It differs from oral triptans by providing a non-invasive, fast-acting option.

What are the primary market barriers for Trudhesa?

Physician familiarity with existing therapies and payer formulary restrictions could slow adoption. Pricing strategy and reimbursement levels significantly influence sales trajectory.

How reliant is Trudhesa on new patient acquisition versus existing migraine treatment switching?

Initial sales likely depend on switching patients from other treatments. Long term, market growth depends on both new diagnoses and existing patient switching.

What regulatory challenges could impact Trudhesa’s commercial success?

Any safety concerns emerging from post-market surveillance or adverse events could prompt label changes or restrict use, impacting sales.

Could off-label use or misuse impact the drug’s profitability?

Yes. Because ergot derivatives have various contraindications, misuse or off-label prescribing could lead to safety issues or regulatory scrutiny.

Citations

[1] American Migraine Foundation. (2022). Migraine facts and figures. Retrieved from https://americanmigrainefoundation.org/resource-library/migraine-facts-and-figures/

[2] FDA. (2023). Trudhesa (dihydroergotamine mesylate nasal spray) approval letter. Retrieved from https://www.fda.gov

[3] Pliant Therapeutics. (2022). Acquisition press release. Retrieved from https://pliantinc.com

[4] Market data and estimates based on industry reports, clinical utilization, and pricing information as of early 2023.